Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ITUS

ITUS (ITUS) Stock Price, News & Analysis

ITUS logo

About ITUS Stock (NASDAQ:ITUS)

Key Stats

Today's Range
$4.61
$4.76
50-Day Range
N/A
52-Week Range
$1.83
$6.43
Volume
69,859 shs
Average Volume
134,373 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Receive ITUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter.

ITUS Stock News Headlines

GMFS Itus Virtus Underground Toy Drive!
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Sherlock wins FR Americas Race 1 at COTA
See More Headlines

ITUS Stock Analysis - Frequently Asked Questions

ITUS Co. (NASDAQ:ITUS) released its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN) and Anixa Biosciences (ANIX).

Company Calendar

Last Earnings
3/09/2018
Today
12/25/2024

Industry, Sector and Symbol

Industry
Patent Owners & Lessors
Sub-Industry
N/A
Current Symbol
NASDAQ:ITUS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:ITUS) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners